tiprankstipranks
Ocular Therapeutix Inc (OCUL)
NASDAQ:OCUL
US Market
OCUL
Ocular Therapeutix
RESEARCH TOOLSreports
Want to see OCUL full AI Analyst Report?

Ocular Therapeutix (OCUL) Stock Forecast & Price Target

1,600 Followers
See the Price Targets and Ratings of:

OCUL Analyst Ratings

Strong Buy
9Ratings
Strong Buy
9 Buy
0 Hold
0 Sell
Based on 9 analysts giving stock ratings to
Ocular
Therapeutix
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

OCUL Stock 12 Month Forecast

Average Price Target

$25.50
▲(159.67% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for Ocular Therapeutix in the last 3 months. The average price target is $25.50 with a high forecast of $31.00 and a low forecast of $18.00. The average price target represents a 159.67% change from the last price of $9.82.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","32":"$32","13.25":"$13.25","19.5":"$19.5","25.75":"$25.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$31.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$25.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,13.25,19.5,25.75,32],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.93,10.627692307692307,12.325384615384614,14.023076923076923,15.72076923076923,17.418461538461536,19.116153846153846,20.813846153846153,22.51153846153846,24.209230769230768,25.906923076923075,27.604615384615382,29.302307692307693,{"y":31,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.93,10.204615384615384,11.47923076923077,12.753846153846155,14.028461538461539,15.303076923076922,16.57769230769231,17.852307692307694,19.126923076923077,20.40153846153846,21.676153846153845,22.950769230769232,24.225384615384616,{"y":25.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.93,9.627692307692307,10.325384615384616,11.023076923076923,11.72076923076923,12.418461538461539,13.116153846153846,13.813846153846153,14.51153846153846,15.20923076923077,15.906923076923077,16.604615384615386,17.302307692307693,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.11,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.1,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.92,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.7,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.04,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.66,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.71,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.14,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.15,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.98,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.33,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.43,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.93,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$31.00Average Price Target$25.50Lowest Price Target$18.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Chardan Capital Analyst forecast on OCUL
Daniil Gataulin
Chardan Capital
Chardan Capital
$21→$23
Buy
134.22%
Upside
Reiterated
06/25/26
Analysts Conflicted on These Healthcare Names: Repligen (NASDAQ: RGEN), Exelixis (NASDAQ: EXEL) and Ocular Therapeutix (NASDAQ: OCUL)
Bank of America Securities Analyst forecast on OCUL
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$27
Buy
174.95%
Upside
Reiterated
06/22/26
Analysts Offer Insights on Healthcare Companies: Sanofi (Other OTC: SNYNF) and Ocular Therapeutix (NASDAQ: OCUL)
H.C. Wainwright Analyst forecast on OCUL
Yi Chen
H.C. Wainwright
H.C. Wainwright
$21→$25
Buy
154.58%
Upside
Reiterated
06/22/26
Analysts Are Bullish on These Healthcare Stocks: NovoCure (NVCR), Ocular Therapeutix (OCUL)
Needham Analyst forecast on OCUL
Serge Belanger
Needham
Needham
$18
Buy
83.30%
Upside
Reiterated
06/18/26
Analysts Are Bullish on These Healthcare Stocks: Prime Medicine, Inc. (PRME), Ocular Therapeutix (OCUL)
Piper Sandler Analyst forecast on OCUL
Biren Amin
Piper Sandler
Piper Sandler
$31
Buy
215.68%
Upside
Reiterated
06/18/26
Piper Sandler Reaffirms Their Buy Rating on Ocular Therapeutix (OCUL)
William Blair Analyst forecast on OCUL
Lachlan Hanbury Brown
William Blair
William Blair
―
Buy
―
Reiterated
06/18/26
Analysts Offer Insights on Healthcare Companies: NeoGenomics (NASDAQ: NEO) and Ocular Therapeutix (NASDAQ: OCUL)
Robert W. Baird Analyst forecast on OCUL
Colleen M. Kusy
Robert W. Baird
Robert W. Baird
$24→$30
Buy
205.50%
Upside
Reiterated
06/18/26
Ocular Therapeutix price target raised to $30 from $24 at BairdOcular Therapeutix price target raised to $30 from $24 at Baird
TD Cowen Analyst forecast on OCUL
Tara Bancroft
TD Cowen
TD Cowen
$20
Buy
103.67%
Upside
Reiterated
05/05/26
Axpaxli’s Strong Phase III Data and Favorable FDA Path Support Buy Rating and Unchanged $20 Price Target
RBC Capital Analyst forecast on OCUL
Lisa Walter
RBC Capital
RBC Capital
$30
Buy
205.50%
Upside
Reiterated
05/05/26
Ocular Therapeutix (OCUL) Gets a Buy from RBC Capital
Clear Street Analyst forecast on OCUL
William Maughan
Clear Street
Clear Street
$21→$28
Buy
185.13%
Upside
Reiterated
03/02/26
Ocular Therapeutix price target raised to $28 from $21 at Clear StreetOcular Therapeutix price target raised to $28 from $21 at Clear Street
Citizens JMP Analyst forecast on OCUL
Jonathan Wolleben
Citizens JMP
Citizens JMP
―
Buy
―
Reiterated
02/17/26
Ocular Therapeutix selloff brings attractive entry point, says CitizensOcular Therapeutix selloff brings attractive entry point, says Citizens
Jefferies Analyst forecast on OCUL
Clara Dong
Jefferies
Jefferies
$28
Buy
185.13%
Upside
Reiterated
02/17/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (Other OTC: SNYNF) and Ocular Therapeutix (NASDAQ: OCUL)
Scotiabank Analyst forecast on OCUL
Greg Harrison
Scotiabank
Scotiabank
$22→$20
Buy
103.67%
Upside
Reiterated
08/06/25
Scotiabank Remains a Buy on Ocular Therapeutix (OCUL)
Raymond James Analyst forecast on OCUL
Dane Leone
Raymond James
Raymond James
$19
Buy
93.48%
Upside
Reiterated
08/04/25
Raymond James Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Chardan Capital Analyst forecast on OCUL
Daniil Gataulin
Chardan Capital
Chardan Capital
$21→$23
Buy
134.22%
Upside
Reiterated
06/25/26
Analysts Conflicted on These Healthcare Names: Repligen (NASDAQ: RGEN), Exelixis (NASDAQ: EXEL) and Ocular Therapeutix (NASDAQ: OCUL)
Bank of America Securities Analyst forecast on OCUL
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$27
Buy
174.95%
Upside
Reiterated
06/22/26
Analysts Offer Insights on Healthcare Companies: Sanofi (Other OTC: SNYNF) and Ocular Therapeutix (NASDAQ: OCUL)
H.C. Wainwright Analyst forecast on OCUL
Yi Chen
H.C. Wainwright
H.C. Wainwright
$21→$25
Buy
154.58%
Upside
Reiterated
06/22/26
Analysts Are Bullish on These Healthcare Stocks: NovoCure (NVCR), Ocular Therapeutix (OCUL)
Needham Analyst forecast on OCUL
Serge Belanger
Needham
Needham
$18
Buy
83.30%
Upside
Reiterated
06/18/26
Analysts Are Bullish on These Healthcare Stocks: Prime Medicine, Inc. (PRME), Ocular Therapeutix (OCUL)
Piper Sandler Analyst forecast on OCUL
Biren Amin
Piper Sandler
Piper Sandler
$31
Buy
215.68%
Upside
Reiterated
06/18/26
Piper Sandler Reaffirms Their Buy Rating on Ocular Therapeutix (OCUL)
William Blair Analyst forecast on OCUL
Lachlan Hanbury Brown
William Blair
William Blair
―
Buy
―
Reiterated
06/18/26
Analysts Offer Insights on Healthcare Companies: NeoGenomics (NASDAQ: NEO) and Ocular Therapeutix (NASDAQ: OCUL)
Robert W. Baird Analyst forecast on OCUL
Colleen M. Kusy
Robert W. Baird
Robert W. Baird
$24→$30
Buy
205.50%
Upside
Reiterated
06/18/26
Ocular Therapeutix price target raised to $30 from $24 at BairdOcular Therapeutix price target raised to $30 from $24 at Baird
TD Cowen Analyst forecast on OCUL
Tara Bancroft
TD Cowen
TD Cowen
$20
Buy
103.67%
Upside
Reiterated
05/05/26
Axpaxli’s Strong Phase III Data and Favorable FDA Path Support Buy Rating and Unchanged $20 Price Target
RBC Capital Analyst forecast on OCUL
Lisa Walter
RBC Capital
RBC Capital
$30
Buy
205.50%
Upside
Reiterated
05/05/26
Ocular Therapeutix (OCUL) Gets a Buy from RBC Capital
Clear Street Analyst forecast on OCUL
William Maughan
Clear Street
Clear Street
$21→$28
Buy
185.13%
Upside
Reiterated
03/02/26
Ocular Therapeutix price target raised to $28 from $21 at Clear StreetOcular Therapeutix price target raised to $28 from $21 at Clear Street
Citizens JMP Analyst forecast on OCUL
Jonathan Wolleben
Citizens JMP
Citizens JMP
―
Buy
―
Reiterated
02/17/26
Ocular Therapeutix selloff brings attractive entry point, says CitizensOcular Therapeutix selloff brings attractive entry point, says Citizens
Jefferies Analyst forecast on OCUL
Clara Dong
Jefferies
Jefferies
$28
Buy
185.13%
Upside
Reiterated
02/17/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (Other OTC: SNYNF) and Ocular Therapeutix (NASDAQ: OCUL)
Scotiabank Analyst forecast on OCUL
Greg Harrison
Scotiabank
Scotiabank
$22→$20
Buy
103.67%
Upside
Reiterated
08/06/25
Scotiabank Remains a Buy on Ocular Therapeutix (OCUL)
Raymond James Analyst forecast on OCUL
Dane Leone
Raymond James
Raymond James
$19
Buy
93.48%
Upside
Reiterated
08/04/25
Raymond James Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ocular Therapeutix

3 Months
Jonathan WollebenCitizens JMP
Success Rate
18/28 ratings generated profit
64%
Average Return
+15.46%
Copying Jonathan Wolleben's trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +15.46% per trade.
1 Year
Biren AminPiper Sandler
Success Rate
13/17 ratings generated profit
76%
Average Return
+19.48%
Copying Biren Amin's trades and holding each position for 1 Year would result in 76.47% of your transactions generating a profit, with an average return of +19.48% per trade.
2 Years
Jonathan WollebenCitizens JMP
Success Rate
25/28 ratings generated profit
89%
Average Return
+99.99%
Copying Jonathan Wolleben's trades and holding each position for 2 Years would result in 89.29% of your transactions generating a profit, with an average return of +99.99% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

OCUL Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
21
23
24
14
16
Buy
12
4
6
4
4
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
33
27
30
18
20
In the current month, OCUL has received 20 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. OCUL average Analyst price target in the past 3 months is 25.50.
Each month's total comprises the sum of three months' worth of ratings.

OCUL Financial Forecast

OCUL Earnings Forecast

Next quarter’s earnings estimate for OCUL is -$0.40 with a range of -$0.42 to -$0.35. The previous quarter’s EPS was -$0.40. OCUL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year OCUL has Performed in-line its overall industry.
Next quarter’s earnings estimate for OCUL is -$0.40 with a range of -$0.42 to -$0.35. The previous quarter’s EPS was -$0.40. OCUL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year OCUL has Performed in-line its overall industry.

OCUL Sales Forecast

Next quarter’s sales forecast for OCUL is $13.20M with a range of $11.50M to $14.73M. The previous quarter’s sales results were $10.79M. OCUL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year OCUL has Performed in-line its overall industry.
Next quarter’s sales forecast for OCUL is $13.20M with a range of $11.50M to $14.73M. The previous quarter’s sales results were $10.79M. OCUL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year OCUL has Performed in-line its overall industry.

OCUL Stock Forecast FAQ

What is OCUL’s average 12-month price target, according to analysts?
Based on analyst ratings, Ocular Therapeutix Inc’s 12-month average price target is 25.50.
    What is OCUL’s upside potential, based on the analysts’ average price target?
    Ocular Therapeutix Inc has 159.67% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is OCUL a Buy, Sell or Hold?
          Ocular Therapeutix Inc has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Ocular Therapeutix Inc’s price target?
            The average price target for Ocular Therapeutix Inc is 25.50. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $31.00 ,the lowest forecast is $18.00. The average price target represents 159.67% Increase from the current price of $9.82.
              What do analysts say about Ocular Therapeutix Inc?
              Ocular Therapeutix Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of OCUL?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.